Global GLP-1 Market Size is valued at USD 50.0 Bn in 2024 and is predicted to reach USD 141.9 Bn by the year 2034 at an 11.1% CAGR during the forecast period for 2025-2034.
The glucagon-like peptide-1 receptor (GLP1R) is a crucial target in treating type 2 diabetes and obesity, given its significant role in regulating blood sugar levels and appetite. GLP-1, a hormone produced in the gut, enhances insulin secretion from pancreatic beta cells in response to glucose, increases insulin expression, and reduces beta-cell apoptosis.
It also lowers glucagon secretion, slows stomach emptying, promotes satiety, and improves glucose disposal in peripheral tissues. Medications known as GLP-1 agonists, including exenatide, liraglutide, and semaglutide, activate the GLP1R, effectively lowering blood sugar levels and facilitating weight loss in individuals with type 2 diabetes.
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns. With diabetes diagnoses significantly increasing and obesity rates skyrocketing, there is a growing demand for effective treatments that manage blood sugar levels and promote weight loss. GLP-1 agonist medications, which target the GLP-1 receptor to regulate insulin, glucagon, and appetite, offer a promising therapeutic approach to these health challenges. As the prevalence of these metabolic disorders continues to rise, the GLP-1 receptor agonist market is set for substantial growth in the coming years.
The GLP-1 market is segmented by type of molecule, active compound used, type of glp-1 agonist drugs, type of agonist, route of administration, target indication. By type of molecule the market is segmented into biologics and small molecules, by active compound used market is categorized into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds. By type of glp-1 agonist drugs market is categorized into long-acting glp-1 agonist and short-acting glp-1 agonist. By type of agonist the market is single-agonist, dual-agonist and tri-agonist, by route of administration market is categorized into oral and parenteral, by target indication market is categorized into Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
The semaglutide segment is a key driver of growth in the GLP-1 receptor agonist market due to its effectiveness and popularity. Marketed as Ozempic and Wegovy, semaglutide has proven highly effective in lowering blood sugar levels in type 2 diabetes patients and promoting significant weight loss in individuals with obesity. Its approval for obesity treatment has broadened its market appeal, especially as global obesity rates rise. Additionally, innovative formulations and administration methods, such as once-weekly injections and oral options, enhance patient convenience and adherence. Semaglutide also offers notable cardiovascular benefits, making it an attractive option for patients with type 2 diabetes and obesity who face increased heart disease risks.
The obesity segment is the fastest-growing area in the GLP-1 receptor agonist market due to several key factors. First, the global prevalence of obesity is rising, with over 40% of adults in the U.S. classified as clinically obese, driving demand for effective weight loss treatments like GLP-1 agonists. Additionally, regulatory approvals for drugs such as semaglutide (Wegovy) specifically for obesity treatment have expanded the patient population significantly. GLP-1 agonists have also shown strong efficacy in clinical trials, with patients achieving an average weight loss of 15-25%, further promoting rapid adoption. Moreover, increasing insurance coverage and affordability of these medications are enhancing patient access, facilitating their utilization in managing obesity.
The APAC region is leading the global GLP-1 receptor agonist market, characterized by rapid growth driven by countries such as China, Japan, and India. This expansion is fueled by a growing healthcare sector, a large target patient population, and significant unmet clinical needs for diabetes and obesity treatments. The rising prevalence of type 2 diabetes and obesity in these countries is increasing demand for effective GLP-1 agonist therapies. Additionally, major pharmaceutical companies are innovating and developing tailored solutions for the APAC market to meet these rising demands. Although specific market share data is limited, the APAC region is recognized as the fastest-growing and a key contributor to the overall GLP-1 receptor agonist market.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 50.0 Billion |
| Revenue Forecast In 2034 | USD 141.9 Billion |
| Growth Rate CAGR | CAGR of 11.1% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target Indication, Dosing Frequency, Delivery System and Payer |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd., Novo Nordisk A/S, PegBio Co., Ltd., Pfizer Inc., QL Biopharmaceutical Co., Ltd., Roche Holding AG, Sanofi S.A., Sciwind Biosciences Co., Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Viking Therapeutics, Inc., Amgen Inc., BioLingus GmbH, D&D Pharmatech Inc., Gmax Biopharm LLC, Hanmi Pharmaceutical Co., Ltd., Vivani Medical, Inc., vTv Therapeutics Inc., Zealand Pharma A/S, Altimmune, Inc., Structure Therapeutics Inc. and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
GLP-1 Market by Type of Molecule -
GLP-1 Market by Active Compound Used -
GLP-1 Market by Type of GLP-1 Agonist Drugs -
GLP-1 Market by Type of Agonist -
GLP-1 Market by Route of Administration-
GLP-1 Market by Target Indication-
GLP-1 Market By Dosing Frequency-
GLP-1 Market By Delivery System-
GLP-1 Market By Payer-
GLP-1 Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global 3D Printed Satellite Market Snapshot
Chapter 4. Global 3D Printed Satellite Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type of Molecule Estimates & Trend Analysis
5.1. by Type of Molecule & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Molecule:
5.2.1. Biologic Peptide GLP-1 Agonists
5.2.2. Small-Molecule Non-Peptide GLP-1 Agonists
Chapter 6. Market Segmentation 2: by Active Compound Used Estimates & Trend Analysis
6.1. by Active Compound Used & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Active Compound Used:
6.2.1. Semaglutide
6.2.2. Tirzepatide
6.2.3. Dulaglutide
6.2.4. Liraglutide
6.2.5. Lixisenatide
6.2.6. Exenatide
6.2.7. Orforglipron
6.2.8. Retatrutide
6.2.9. Survodutide
6.2.10. Other Active Compounds
6.2.11. Tirzepatide
Chapter 7. Market Segmentation 3: by Type of GLP-1 Agonist Drugs Estimates & Trend Analysis
7.1. by Type of GLP-1 Agonist Drugs & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of GLP-1 Agonist Drugs:
7.2.1. Long-acting GLP-1 Agonist
7.2.2. Short-acting GLP-1 Agonist
Chapter 8. Market Segmentation 4: by Type of Agonist Estimates & Trend Analysis
8.1. by Type of Agonist & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Agonist:
8.2.1. Single agonist
8.2.2. Dual agonist
8.2.3. Tri-agonist
Chapter 9. Market Segmentation 5: by Route of Administration Estimates & Trend Analysis
9.1. by Route of Administration & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
9.2.1. Oral
9.2.2. Parenteral
Chapter 10. Market Segmentation 6: by Target Indication Estimates & Trend Analysis
10.1. by Target Indication & Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:
10.2.1. Alzheimer’s Disease
10.2.2. Non-Alcoholic Steatohepatitis
10.2.3. Obesity
10.2.4. Sleep Apnea
10.2.5. Type 2 Diabetes
Chapter 11. Market Segmentation 7: by Dosing Frequency Estimates & Trend Analysis
11.1. by Dosing Frequency & Market Share, 2024 & 2034
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Dosing Frequency:
11.2.1. Daily
11.2.2. Weekly
11.2.3. Monthly or Extended-Interval
Chapter 12. Market Segmentation 8: by Delivery System Estimates & Trend Analysis
12.1. by Delivery System & Market Share, 2024 & 2034
12.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery System:
12.2.1. Disposable Pre-filled Pen
12.2.2. Auto-Injector
12.2.3. Pre-filled Syringe
12.2.4. Oral Tablet / Capsule
Chapter 13. Market Segmentation 9: by Payer Estimates & Trend Analysis
13.1. by Target Indication & Market Share, 2024 & 2034
13.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:
13.2.1. Retail Pharmacy – Commercial Insurance
13.2.2. Retail Pharmacy – Government (Medicare / Medicaid)
13.2.3. Specialty / Mail-Order Pharmacy
13.2.4. Self-Pay
Chapter 14. 3D Printed Satellite Market Segmentation 10: Regional Estimates & Trend Analysis
14.1. North America
14.1.1. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.1.2. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.1.3. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.1.4. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.1.5. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.1.6. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.1.7. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.1.8. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.1.9. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.1.10. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
14.2. Europe
14.2.1. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.2.2. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.2.3. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.2.4. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.2.5. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.2.6. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.2.7. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.2.8. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.2.9. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.2.10. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
14.3. Asia Pacific
14.3.1. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.3.2. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.3.3. Asia-Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.3.4. Asia-Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.3.5. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.3.6. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.3.7. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.3.8. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.3.9. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.3.10. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
14.4. Latin America
14.4.1. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.4.2. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.4.3. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.4.4. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.4.5. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.4.6. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.4.7. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.4.8. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.4.9. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.4.10. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
14.5. Middle East & Africa
14.5.1. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.5.2. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.5.3. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.5.4. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.5.5. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.5.6. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.5.7. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.5.8. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.5.9. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.5.10. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 15. Competitive Landscape
15.1. Major Mergers and Acquisitions/Strategic Alliances
15.2. Company Profiles
15.2.1. AstraZeneca plc
15.2.2. Boehringer Ingelheim International GmbH
15.2.3. Eli Lilly and Company
15.2.4. Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd.
15.2.5. Novo Nordisk A/S
15.2.6. PegBio Co., Ltd.
15.2.7. Pfizer Inc.
15.2.8. QL Biopharmaceutical Co., Ltd.
15.2.9. Roche Holding AG
15.2.10. Sanofi S.A.
15.2.11. Sciwind Biosciences Co., Ltd.
15.2.12. Tonghua Dongbao Pharmaceutical Co., Ltd.
15.2.13. Viking Therapeutics, Inc.
15.2.14. Amgen Inc.
15.2.15. BioLingus GmbH
15.2.16. D&D Pharmatech Inc.
15.2.17. Gmax Biopharm LLC
15.2.18. Hanmi Pharmaceutical Co., Ltd.
15.2.19. Vivani Medical, Inc.
15.2.20. vTv Therapeutics Inc.
15.2.21. Zealand Pharma A/S
15.2.22. Altimmune, Inc.
15.2.23. Structure Therapeutics Inc.
15.2.24. Other Prominent Players